Investment firm HC Wainwright lowers price target for Hookipa Pharma.

HC Wainwright lowered its price target for Hookipa Pharma (NASDAQ:HOOK) from $6.50 to $5.00, while Royal Bank of Canada reaffirmed an "outperform" rating with a $5.00 target price. Hookipa Pharma reported Q1 EPS of ($0.11) vs. consensus estimates of ($0.20), beating expectations by $0.09. The company has a market cap of $79.76 million, a price-to-earnings ratio of -0.92, and a beta of 1.02.

April 26, 2024
3 Articles

Further Reading